Pharmaceuticals had long been a focus of regulators and private plaintiffs and an area that regularly saw novel theories of harm. Whether it be the recently-in-focus Orange Book listings, developments in patent settlement law, M&A and exclusive licensing enforcement trends, or recent European decisions regarding the jurisdictional nexus required for enforcement, pharmaceutical antitrust law was constantly changing in the U.S. and Europe.
Antitrust Webinar Series
